

Doctor's Order Sheet
**pembrolizumab 2 mg/kg -
 PACLitaxel 175 - CISplatin 50
 - Zirabev® (bevacizumab)**

Name: _____
 HCN: _____
 Date of Birth: _____

15 mg/kg Regimen (Part I) Cycle 7 +

ARIA Protocol Name: pembrolizumab2 PACLitaxel175 CISplatin50 bevacizumab15

Adult Chemotherapy - Gynecologic Oncology

Persistent, Recurrent or Metastatic Cervical Cancer Treatment



CC5390 0349 06 2023

Allergies: No Known

Date: DD/MONTH/YYYY Planned Administration Date: DD/MONTH/YYYY
 Cycle of **Cycle Duration: 21 days** Date of previous cycle: DD/MONTH/YYYY

MAY PROCEED WITH DOSES AS WRITTEN IF:

- ANC **greater than or equal to** 1.0 X 10⁹/L and platelets **greater than or equal to** 100 X 10⁹/L, otherwise notify Gynecologic Oncologist.
- LFT's and Bilirubin assessed.
- Creatinine clearance assessed.
- Dipstick urine or laboratory urinalysis for protein assessed.
- Thyroid function assessed.

PREMEDICATIONS (FOR HOSPITAL PHARMACY):

Other: _____

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.

Doctor's Order Sheet
**pembrolizumab 2 mg/kg -
 PACLitaxel 175 - CISplatin 50
 - Zirabev® (bevacizumab)**

Name: _____

HCN: _____

Date of Birth: _____

15 mg/kg Regimen (Part II) Cycles 7 +

ARIA Protocol Name: pembrolizumab2 PACLitaxel175 CISplatin50 bevacizumab15

Adult Chemotherapy - Gynecologic Oncology

Persistent, Recurrent or Metastatic Cervical Cancer Treatment



CC5390 0349 06 2023

Weight: _____ kg Height: _____ cm Body Surface Area (BSA) = _____

CHEMOTHERAPY (FOR HOSPITAL PHARMACY):

pembrolizumab 2 mg/kg X Weight (kg) = _____ mg (maximum dose 200mg)

IV in 50 mL normal saline over 30 minutes on day 1

Zirabev® (bevacizumab) 15 mg/kg X Weight (kg) = _____ mg

Dose modification: **Zirabev® (bevacizumab) 15 mg/kg X weight (kg) - _____ % = _____ mg**

IV in 100 to 250 mL normal saline on day 1 over:

— **60** minutes during **Cycle 1**;

— If tolerated without reaction - **30** minutes during **Cycle 2** and all other cycles

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.